HS Code:
Laxatives fall under the broader category of pharmaceutical products, often classified under HS Code 3004 (Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses). This category includes a variety of over-the-counter and prescription laxative products used to treat constipation and promote bowel movements. These products can be in the form of tablets, capsules, powders, or liquids, and are derived from natural or synthetic sources. The global trade of laxatives is driven by increasing demand due to aging populations, dietary changes, and rising awareness of digestive health. The market is influenced by regulatory standards for pharmaceuticals, varying consumer preferences, and the growing trend of self-medication.
Total Trade Volume
Approximately $1.2 billion USD
Data from 2022
Source
United Nations Comtrade Database, International Trade Centre (ITC)
$320 million USD
26.7% of total trade of total trade
Increasing
$180 million USD
15.0% of total trade of total trade
Stable
$150 million USD
12.5% of total trade of total trade
Increasing
$120 million USD
10.0% of total trade of total trade
Stable
$90 million USD
7.5% of total trade of total trade
Decreasing
Average Rate
5.2% ad valorem
Highest Rate
12% (imposed by certain developing countries with protective pharmaceutical policies)
Lowest Rate
0% (under free trade agreements like EU Single Market or USMCA)
Rising demand for natural and herbal laxatives
Increased exports from countries with access to herbal raw materials like India and China, influencing product innovation and market segmentation.
2021-2023
Growth in aging population
Higher demand in developed markets such as the US and Japan, driving import volumes and encouraging localized production.
2020-2023
E-commerce and direct-to-consumer sales
Shift in distribution channels, reducing trade barriers for smaller exporters and increasing global market access.
2022-2023
The European Union introduced stricter guidelines on the use of certain synthetic laxative ingredients, requiring reformulation for compliance.
March 2023
Potential delays in exports to EU markets and increased production costs for manufacturers.
A bilateral agreement reduced tariffs on certain pharmaceutical products, including laxatives, to promote trade between the two countries.
September 2022
Boosted Indian exports to the US, strengthening India's position as a key supplier.
Ongoing disruptions due to geopolitical tensions and post-COVID recovery have affected the supply of raw materials for laxative production.
Throughout 2022-2023
Increased costs and delays in trade, particularly for countries reliant on imported active pharmaceutical ingredients (APIs).